Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2012. The filing identifies the registrant as Capstone Therapeutics Corp., a development-stage biotechnology company; the request metadata refers to Capstone Holding Corp. The financial statements are unaudited.
Business Context and Reporting Period
The company was developing AZX100 and Chrysalin (TP508), but entered a cash-preservation and wind-down phase. In January 2012, it ceased clinical development of AZX100 for dermal scarring, except for certain required or contracted activities, and ceased all development activities for TP508. The company returned TP508-related intellectual property to the University of Texas Medical Branch in March 2012 and retained no rights to that program.
As of March 31, 2012, the company had four employees and was focused on partnering or licensing AZX100, evaluating strategic transactions, completing remaining regulatory and statutory obligations, and maintaining public-company compliance.
Financial Position and Key Metrics
| Metric | March 31, 2012 / Q1 2012 | Comparable period or prior date |
|---|---|---|
| Revenue | No revenue reported; the company had no revenue-producing operations | Not provided |
| General and administrative expense | $424,000 | $1.165 million in Q1 2011 |
| Research and development expense | $556,000 | $2.082 million in Q1 2011 |
| Total operating expenses | $980,000 | $3.247 million in Q1 2011 |
| Net loss | $976,000, or $0.02 per basic and diluted share | $3.237 million, or $0.08 per share, in Q1 2011 |
| Cash flow from operating activities | $(661,000) | $(2.747 million) in Q1 2011 |
| Cash and cash equivalents | $13.117 million | $13.778 million at December 31, 2011; $21.640 million at March 31, 2011 |
| Total assets | $13.785 million | $14.696 million at December 31, 2011 |
| Current liabilities | $156,000 | $119,000 at December 31, 2011 |
| Debt | No debt is disclosed in the presented balance sheet | Not applicable |
| Shares outstanding | 40.885 million as of April 30, 2012 | 40.775 million at December 31, 2011 |
Cash declined by approximately $661,000 during the quarter, principally reflecting operating cash use. No investing or financing cash flows were reported for the quarter. The filing does not provide a meaningful operating margin because the company reported no revenue.
Material Changes Versus Q1 2011 and December 31, 2011
- General and administrative expense decreased approximately 64%, primarily because of the late-2011 workforce reduction and wind-down actions.
- Research and development expense decreased approximately 73% as clinical and other development activities were curtailed.
- Total operating expenses decreased approximately 70%, and net loss decreased approximately 70% year over year.
- Operating cash burn decreased from $2.747 million to $661,000.
- Cash and cash equivalents decreased $661,000 from December 31, 2011, while total assets decreased $911,000.
- Accounts payable increased from $77,000 to $144,000, while total current liabilities increased from $119,000 to $156,000.
- The company ceased TP508 development and surrendered related intellectual property, leaving AZX100 as the principal remaining development asset.
Outlook, Risks, Contingencies, and Unusual Items
Management estimated that, if the wind-down continued through 2012, planned expenditures would be approximately $2.5 million to $3.0 million, excluding potentially significant costs related to the qui tam litigation. Management stated that cash and short-term investments at March 31, 2012 were expected to fund presently projected cash and working-capital needs for the next year.
The company stated that substantial additional capital would be required to resume clinical trials and complete the research, manufacturing, and regulatory work needed for potential FDA approval of AZX100. Possible funding sources include debt or equity offerings, joint development arrangements, sales of development rights, or licensing transactions, but availability and terms are uncertain.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, principally because the timing and outcome of the qui tam litigation could affect strategic transactions, any restart of clinical operations, potential shareholder distributions, liquidity, and the company’s ability to continue operations. The financial statements do not include adjustments that might result from this uncertainty.
The qui tam complaint alleges violations of federal, state, and municipal false-claims laws and related anti-kickback allegations concerning the former bone-growth-stimulation business sold in 2003. The plaintiff seeks civil penalties and treble damages that could exceed the company’s financial resources. The United States declined to intervene, no trial date had been set, and discovery was open. Management believed a material loss was not reasonably possible based on currently available information, but acknowledged that an adverse outcome could materially impair financial position, liquidity, and operations.
No material changes to previously disclosed risk factors were reported. Disclosure controls and procedures were assessed as effective, and no material changes to internal control over financial reporting were reported.
Important Facts for Investors to Verify
- Verify the registrant’s legal name and corporate identity, given the filing’s identification of Capstone Therapeutics Corp. versus the metadata reference to Capstone Holding Corp.
- Confirm the company’s current cash balance, cash runway, and actual 2012 wind-down expenditures, including litigation costs.
- Monitor the status and potential financial exposure of the qui tam litigation, including any settlement, judgment, or trial developments.
- Assess whether the company can successfully license or partner AZX100 and on what economic terms.
- Verify that TP508 rights remain surrendered and determine the remaining contractual, regulatory, and manufacturing obligations associated with AZX100.
- Consider the disclosed going-concern uncertainty and the potential need for additional capital or a strategic transaction.
- Review dilution risk from potential financing and the 3.473 million outstanding options and warrants with exercise prices ranging from $0.26 to $7.83 per share.